Why Novavax Stock Got Mashed on Monday
Novavax (NASDAQ: NVAX), an up-and-down coronavirus stock, had a down day on Monday. The vaccine specialist's share price took a 5% hit after the company reported earnings that fell short of expectations. For its second quarter, Novavax earned just under $186 million in total revenue, which was well under the more than $298 million in the same period last year.